Global Neutropenia Treatment Market Report 2019-2027

DUBLIN, Sept. 20, 2019 /PRNewswire/ -- The "Global Neutropenia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019-2027" report has been added to's offering.

The global Neutropenia treatment market was valued at USD 11,279.2 Mn in 2018 and is expected to reach USD 17,331.4 Mn by 2027, expanding at a CAGR of 5.0% from 2019 to 2027.

Market Insights

In 2018, Granulocyte-colony stimulating factor (G-CSF) drug class dominated the overall neutropenia treatment market being the first-line of action and only target-specific drug approved by regulatory bodies. G-CSF stimulates the production of granulocytes in patients suffering from neutropenia leading to an increase in the count of white blood cells. In cancer patients, G-CSF is prescribed as primary prophylaxis which refers to its application post the first cycle of chemotherapy in cancer patients but before the development of neutropenia to prevent further complications.

The overall pipeline of neutropenia treatment seems promising with products present in phase III of clinical trials such as SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon (Shanghai) Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.) and Plinabulin (BeyondSpring Pharmaceuticals Inc.) among others.

During the forecast period from 2019 to 2027, Asia Pacific was identified as the fastest-growing region in neutropenia treatment due to rising prevalence of leukemia in the Asia Pacific, increasing awareness related to neutropenia diagnostics & treatment, and evolving accessibility for novel drugs entering in the market by 2027.

Key Market Movements

    --  Rising awareness specific to neutropenia & chemotherapy-related
        side-effects and developing diagnostic technology is anticipated to
        assist the overall growth of neutropenia treatment in the near future
    --  Promising drug pipeline with around 5 drugs in phase III clinical trials
        to treat neutropenia is responsible for significant growth
    --  Increasing prevalence of leukemia is expected to raise the risk of
        neutropenia especially post-chemotherapy

Market Competition Assessment

The neutropenia treatment market will significantly grow and key companies operating in this market are promoting research & development activities as well as awareness related to neutropenia treatment. The key market strategies used by companies present in this market are increasing awareness related to prophylactic measures, early diagnosis, and effective treatment of neutropenia.

The companies present in this market are

    --  Amgen, Inc.
    --  Pfizer, Inc.
    --  Myelo Therapeutics, Inc.
    --  Cellerant Therapeutics, Inc.
    --  Sandoz (Subsidary of Novartis AG)
    --  BeyondSpring Pharmaceuticals Inc.
    --  Enzychem Lifesciences Corporation
    --  Spectrum Pharmaceuticals, Inc.
    --  Tianjin SinoBiotech Ltd.
    --  S&D Pharma SK s.r.o.
    --  Samsung Medical Center
    --  Generon (Shanghai) Corporation Ltd.
    --  PhytoHealth Corporation
    --  Dong-A ST Co., Ltd.

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary
2.1. Global Neutropenia Treatment Market Portraiture
2.2. Global Neutropenia Treatment Market, by Type of Drug Class, 2018 (US$ Mn)
2.3. Global Neutropenia Treatment Market, by Geography, 2018 Vs 2027 (Value %)

Chapter 3. Global Neutropenia Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Neutropenia Treatment Market, by Type of Drug Class, 2017 - 2027 (US$ Mn)
4.1. Overview
4.2. Granulocyte-colony stimulating factor (G-CSF)
4.3. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
4.4. Antibiotics
4.5. Antifungal
4.6. Antiviral

Chapter 5. Global Neutropenia Treatment Market, Pipeline Analysis
5.1. Overview
5.2. Plinabulin - Phase 2/3 (BeyondSpring Pharmaceuticals Inc.)
5.3. EC-18 - Phase 2 (Enzychem Lifesciences Corporation)
5.4. SPI-2012 - Phase 3 (Spectrum Pharmaceuticals, Inc.)
5.5. rHSA-GCSF 2.4mg - Phase 2 (Tianjin SinoBiotech Ltd.)
5.6. Probio-Fix Inum - Phase 2 (S&D Pharma SK s.r.o.)
5.7. Pegteograstim - Phase 2 (Samsung Medical Center)
5.8. F-627 - Phase 3 (Generon (Shanghai) Corporation Ltd.)
5.9. Astragalus polysaccharides 500 mg - Phase 2 (PhytoHealth Corporation)
5.10. Leucostim - Phase 3 (Dong-A ST Co., Ltd.)
5.11. myelo001 - Phase 3 (Myelo Therapeutics, Inc.)
5.12. Romyelocel-L - Phase 3 (Cellerant Therapeutics, Inc.)

Chapter 6. Global Neutropenia Treatment Market, by Geography, 2017 - 2027 (US$ Mn)

Chapter 7. Company Profiles
7.1. Business Description
7.2. Financial Information (Subject to data availability)
7.3. Product Portfolio
7.4. Key Developments

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets